In the first phase of the study, 23 patients were enrolled and 120 mg of ARQ 197 commandments are far fourteen of these patients evaluable for efficacy. In addition to the patients with confirmed partial response, ten of the evaluable patients stable stable disease online . Preliminary data from the first stage is planned to be presented at the Connective Tissue Oncology Society meeting in November 2008.
ArQule achieved clinical milestone in MIT study with ARQ 197 – Confirmed tumor response in clear cell sarcoma resulted in extended trialArQule is completing its scientific, legal and economic analyzes related to the overall Phase 2 development program for ARQ 197th The company plans more details on this more details on this program this month.
MedSurg Nursing Journal – Issue to do The July / August 2009 issue MedSurg Nursing Journal offers the following:.